Clinical Trial Update: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite-stable metastatic colorectal cancer. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Evorpacept (ALX148)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING